Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Fibrogen Inc CS (FGEN)

Fibrogen Inc CS (FGEN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 30,919
  • Shares Outstanding, K 101,044
  • Annual Sales, $ 29,620 K
  • Annual Income, $ -47,580 K
  • EBIT $ -113 M
  • EBITDA $ -112 M
  • 60-Month Beta 0.86
  • Price/Sales 1.03
  • Price/Cash Flow N/A
  • Price/Book N/A
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -1.23
  • Most Recent Earnings $-0.16 on 05/12/25
  • Next Earnings Date N/A
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical - Drugs

Options Overview Details

View History
  • Implied Volatility 150.81% ( -50.53%)
  • Historical Volatility 70.09%
  • IV Percentile 20%
  • IV Rank 9.78%
  • IV High 1,051.52% on 04/04/25
  • IV Low 53.20% on 08/21/24
  • Put/Call Vol Ratio 0.00
  • Today's Volume 100
  • Volume Avg (30-Day) 67
  • Put/Call OI Ratio 0.24
  • Today's Open Interest 17,928
  • Open Int (30-Day) 17,633

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/25
See More
  • Average Estimate -0.09
  • Number of Estimates 2
  • High Estimate 0.04
  • Low Estimate -0.22
  • Prior Year -0.16
  • Growth Rate Est. (year over year) +43.75%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.2703 +13.21%
on 04/17/25
0.3529 -13.29%
on 04/29/25
+0.0284 (+10.23%)
since 04/16/25
3-Month
0.2300 +33.04%
on 04/09/25
0.8775 -65.13%
on 02/20/25
-0.2485 (-44.82%)
since 02/14/25
52-Week
0.1800 +70.00%
on 11/13/24
1.5300 -80.00%
on 07/23/24
-0.9340 (-75.32%)
since 05/16/24

Most Recent Stories

More News
FibroGen: Q1 Earnings Snapshot

FibroGen: Q1 Earnings Snapshot

FGEN : 0.3060 (+1.32%)
FibroGen Reports First Quarter 2025 Financial Results and Provides Business Update

FGEN : 0.3060 (+1.32%)
FibroGen to Report First Quarter 2025 Financial Results

FGEN : 0.3060 (+1.32%)
FibroGen to Participate in the 24th Annual Needham Virtual Healthcare Conference

FGEN : 0.3060 (+1.32%)
FibroGen Announces Publication of Results from Phase 1 Monotherapy Study of FG-3246 in Patients with Metastatic Castration-Resistant Prostate Cancer in the Journal of Clinical Oncology

FGEN : 0.3060 (+1.32%)
FibroGen: Q4 Earnings Snapshot

FibroGen: Q4 Earnings Snapshot

FGEN : 0.3060 (+1.32%)
FibroGen Reports Fourth Quarter and Full Year 2024 Financial Results

FGEN : 0.3060 (+1.32%)
FibroGen to Report Fourth Quarter and Full Year 2024 Financial Results

FGEN : 0.3060 (+1.32%)
FibroGen Announces the Sale of FibroGen China to AstraZeneca for Approximately $160 Million

FGEN : 0.3060 (+1.32%)
FibroGen Appoints David DeLucia as Chief Financial Officer

FibroGen appoints David DeLucia as Chief Financial Officer, effective December 16, 2024, following Juan Graham's departure.Quiver AI SummaryFibroGen, Inc. has appointed David DeLucia as the new Chief Financial...

FGEN : 0.3060 (+1.32%)

Business Summary

FibroGen, Inc. is a research-based biotechnology company. It is focused on the discovery, development, and commercialization of therapeutic agents for treatment of anemia, fibrosis, cancer, and other serious unmet medical needs. The Company develops Roxadustat that is in Phase III clinical development...

See More

Key Turning Points

3rd Resistance Point 0.3213
2nd Resistance Point 0.3159
1st Resistance Point 0.3109
Last Price 0.3060
1st Support Level 0.3005
2nd Support Level 0.2951
3rd Support Level 0.2901

See More

52-Week High 1.5300
Fibonacci 61.8% 1.0143
Fibonacci 50% 0.8550
Fibonacci 38.2% 0.6957
Last Price 0.3060
52-Week Low 0.1800

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar